Fertility Preservation in BRCA1/2 Germline Mutation Carriers: An Overview

Fertility Preservation in BRCA1/2 Germline Mutation Carriers: An Overview

BRCA1 and BRCA2 mutations are responsible for a higher incidence of breast and ovarian cancer (from 55% up to 70% vs. 12% in the general population). If their functions have been widely investigated in the onset of these malignancies, still little is known about their role in fertility impairment. C...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Erica Silvestris, Gennaro Cormio, Vera Loizzi, Giacomo Corrado, Francesca Arezzo, Easter Anna Petracca
Format:	Artykuł
Język:	English
Wydane:	MDPI AG 2024-05-01
Seria:	Life
Hasła przedmiotowe:	BRCA fertility preservation oncofertility ovarian stem cell premature ovarian failure
Dostęp online:	https://www.mdpi.com/2075-1729/14/5/615

Podobne zapisy

The Late Effects of Cancer Treatment on Female Fertility and the Current Status of Fertility Preservation—A Narrative Review
od: Kenny A. Rodriguez-Wallberg, i wsp.
Wydane: (2023-05-01)

Reproductive outcomes in women with BRCA 1/2 germline mutations: A retrospective observational study and literature review
od: Dellino Miriam, i wsp.
Wydane: (2024-08-01)

Impact of Breast Cancer and Germline BRCA Pathogenic Variants on Fertility Preservation in Young Women
od: Elze Prokurotaite, i wsp.
Wydane: (2023-04-01)

Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome
od: Ashour M, i wsp.
Wydane: (2019-07-01)

Methods for preserving fertility in childhood cancer patients
od: L. V. Adamyan, i wsp.
Wydane: (2024-01-01)

An explainable machine learning ensemble model to predict the risk of ovarian cancer in BRCA-mutated patients undergoing risk-reducing salpingo-oophorectomy
od: Maria Colomba Comes, i wsp.
Wydane: (2023-07-01)

Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru
od: Yomali Ferreyra, i wsp.
Wydane: (2023-08-01)

Royan Institute First Attempts: Autotransplantation of Vitrified Human Ovarian Tissue in Cancer Patients
od: Naeimeh Sadat Abtahi, i wsp.
Wydane: (2023-11-01)

Fertility Preservation in Breast Cancer Patients Under Special Consideration of Ovarian Stimulation for Fertility Purposes
od: Sebastian Findeklee, i wsp.
Wydane: (2020-11-01)

Association Between Germline BRCA1/2 Gene Variants and Clinicopathological Features of Ovarian Cancer
od: Luo Y, i wsp.
Wydane: (2024-01-01)

A Systematic Review of Ovarian Tissue Transplantation Outcomes by Ovarian Tissue Processing Size for Cryopreservation
od: Ashley A. Diaz, i wsp.
Wydane: (2022-06-01)

The Experience of Fertility Preservation in a Single Tertiary Center in Korea
od: Yae Ji Choi, i wsp.
Wydane: (2022-04-01)

Fertility Preservation for Child and Adolescent Cancer Patients in Asian Countries
od: Seido Takae, i wsp.
Wydane: (2019-10-01)

Corrigendum: Fertility Preservation for Child and Adolescent Cancer Patients in Asian Countries
od: Seido Takae, i wsp.
Wydane: (2020-04-01)

Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review
od: Lisa Krassuski, i wsp.
Wydane: (2019-08-01)

Editorial: Fertility preservation in the pediatric population
od: Asma J. Chattha, i wsp.
Wydane: (2023-02-01)

Reproductive issues in carriers of germline pathogenic variants in the BRCA1/2 genes: an expert meeting
od: Barbara Buonomo, i wsp.
Wydane: (2021-09-01)

The Features of BRCA1 and BRCA2 Germline Mutations in Hakka Ovarian Cancer Patients: BRCA1 C.536 A>T Maybe a Founder Mutation in This Population
od: Luo Y, i wsp.
Wydane: (2022-03-01)

OTO-IVM is a method of fertility preservation for patients with ovarian tumors
od: O. E. Lavrinovich, i wsp.
Wydane: (2024-09-01)

A challenge of fertility preservation in the setting of cervical cancer - a clinical case
od: I. E. Dmitrieva, i wsp.
Wydane: (2021-04-01)

BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients
od: Tarinee Manchana, i wsp.
Wydane: (2020-08-01)

Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer
od: Tingyan Shi, i wsp.
Wydane: (2018-07-01)

BRCA1 and BRCA2 and Inherited Predisposition to Breast and Ovarian Cancers
od: Patricia N. Tonin
Wydane: (2002-12-01)

Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects
od: Ana Peixoto, i wsp.
Wydane: (2020-07-01)

Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients
od: Yunuo Zhang, i wsp.
Wydane: (2022-08-01)

Quantitative Analysis of BRCA1 and BRCA2 Germline Splicing Variants Using a Novel RNA-Massively Parallel Sequencing Assay
od: Suzette Farber-Katz, i wsp.
Wydane: (2018-07-01)

Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia
od: Dorra Ben Ayed-Guerfali, i wsp.
Wydane: (2021-03-01)

Age-specific breast and ovarian cancer risks associated with germline BRCA1 or BRCA2 pathogenic variants – an Asian study of 572 familiesResearch in context
od: Weang-Kee Ho, i wsp.
Wydane: (2024-03-01)

Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations
od: Robert L. Hollis, i wsp.
Wydane: (2018-01-01)

An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers
od: Ewa Przybytkowski, i wsp.
Wydane: (2020-03-01)

A dozen years of ovarian tissue cryopreservation at a pediatric hospital: tracking program and patient metrics while adapting to increasing needs
od: Kathryn L. McElhinney, M.D., i wsp.
Wydane: (2024-06-01)

Next-generation sequencing of BRCA1 and BRCA2 genes for rapid detection of germline mutations in hereditary breast/ovarian cancer
od: Arianna Nicolussi, i wsp.
Wydane: (2019-04-01)

Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland
od: Tomasz Kluz, i wsp.
Wydane: (2018-02-01)

Selected aspects of genetic counselling for <it>BRCA1 </it>mutation carriers
od: Gronwald Jacek
Wydane: (2007-03-01)

Epigenetic editing of BRCA1 promoter increases cisplatin and olaparib sensitivity of ovarian cancer cells
od: Wanhong He, i wsp.
Wydane: (2024-12-01)

Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer
od: Yong Jae Lee, i wsp.
Wydane: (2020-03-01)

Anti-müllerian hormone levels and antral follicle count in women with a BRCA1 or BRCA2 germline pathogenic variant: A retrospective cohort study
od: Laurie Denis-Laroque, i wsp.
Wydane: (2021-10-01)

Survey of understanding and awareness of fertility preservation in pediatric patients: Is conversation about fertility preservation unpleasant for pediatric patients?
od: Seido Takae, i wsp.
Wydane: (2023-01-01)

Fertility preservation in patients with breast cancer. Literature review
od: Marina V. Kiseleva, i wsp.
Wydane: (2023-12-01)

Incidence of premature ovarian failure and early menopause in carriers of <i>BRCA1</i> pathogenic variants
od: Sandra D. Rshtuni, i wsp.
Wydane: (2022-11-01)